Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNM Immunome	$10.30 +3.5%	$9.69	$5.15 ▼ $16.73	$866.10M	1.93	605,789 shs	1.04 million shs
MLTX MoonLake Immunotherapeutics	$55.89 +3.2%	$50.51	$31.42 ▼ $58.26	$3.48B	1.27	469,826 shs	257,570 shs
MTSR Metsera	$33.05 +0.8%	$33.31	$12.30 ▼ $47.40	$3.47B	N/A	1.53 million shs	1.24 million shs
PTGX Protagonist Therapeutics	$57.48 +2.6%	$54.15	$33.31 ▼ $60.60	$3.49B	2.33	605,768 shs	470,129 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNM Immunome	+3.52%	+0.19%	-10.04%	+21.32%	-32.24%
MLTX MoonLake Immunotherapeutics	+3.18%	+2.76%	+0.27%	+43.57%	+13.30%
MTSR Metsera	+0.76%	+6.13%	-17.35%	+21.06%	+3,304,999,900.00%
PTGX Protagonist Therapeutics	+2.57%	+2.51%	+6.07%	+25.89%	+38.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNM Immunome	1.8618 of 5 stars	3.5	0.0	0.0	0.0	2.7	2.5	0.0
MLTX MoonLake Immunotherapeutics	1.7764 of 5 stars	3.4	1.0	0.0	0.0	1.8	2.5	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	1.8176 of 5 stars	2.5	3.0	0.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNM Immunome	3.00	Buy	$22.50	118.45% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	33.17% Upside
MTSR Metsera	3.00	Buy	$55.00	66.41% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	16.91% Upside

Current Analyst Ratings Breakdown

Latest IMNM, MLTX, MTSR, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	IMNM Immunome	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
7/28/2025	MLTX MoonLake Immunotherapeutics	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/28/2025	MLTX MoonLake Immunotherapeutics	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNM Immunome	$12.59M	71.22	N/A	N/A	$3.09 per share	3.33
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.57 per share	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	$4.28 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	8.23	$4.63 per share	12.41	$10.74 per share	5.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	$275.19M	$0.70	82.12	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)

Latest IMNM, MLTX, MTSR, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
7/28/2025	Q2 2025	MTSR Metsera	N/A	-$0.66	N/A	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNM Immunome	N/A	12.13	12.13
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
MTSR Metsera	N/A	5.26	5.26
PTGX Protagonist Therapeutics	N/A	16.97	16.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMNM Immunome	44.58%
MLTX MoonLake Immunotherapeutics	93.85%
MTSR Metsera	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
IMNM Immunome	7.69%
MLTX MoonLake Immunotherapeutics	12.02%
MTSR Metsera	N/A
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNM Immunome	40	87.05 million	80.35 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.51 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable

IMNM, MLTX, MTSR, and PTGX Headlines

Recent News About These Companies

Charles Schwab Investment Management Inc. Sells 20,691 Shares of Protagonist Therapeutics, Inc. $PTGX

3 hours ago | marketbeat.com

Vanguard Group Inc. Has $206.85 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 22 at 3:18 AM | marketbeat.com

Invesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:42 AM | marketbeat.com

Deutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:24 AM | marketbeat.com

E Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 18, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment Board

August 15, 2025 | marketbeat.com

Informed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 13, 2025 | marketbeat.com

Knott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 12, 2025 | marketbeat.com

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?

August 12, 2025 | finance.yahoo.com

Wedbush Issues Optimistic Estimate for PTGX Earnings

August 12, 2025 | americanbankingnews.com

Wedbush Has Positive Estimate for PTGX Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Expects Higher Earnings for Protagonist Therapeutics

August 9, 2025 | marketbeat.com

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8, 2025 | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8, 2025 | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7, 2025 | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7, 2025 | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

Jupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, MLTX, MTSR, and PTGX Company Descriptions

Immunome NASDAQ:IMNM

$10.30 +0.35 (+3.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.30 +0.00 (+0.05%)

As of 08/22/2025 04:20 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

MoonLake Immunotherapeutics NASDAQ:MLTX

$55.89 +1.72 (+3.18%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$54.75 -1.14 (-2.04%)

As of 08/22/2025 06:58 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera NASDAQ:MTSR

$33.05 +0.25 (+0.76%)

As of 08/22/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Protagonist Therapeutics NASDAQ:PTGX

$57.48 +1.44 (+2.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$57.48 +0.01 (+0.01%)

As of 08/22/2025 06:02 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time